Načítá se...
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents
BACKGROUND: Traditional phase I trials are designed to be conservative. Many times a traditional phase I trial design stops at a dose level below the maximal tolerated dose (MTD), thus potentially treating patients at a suboptimal level in all subsequent trials. This has been confirmed by our recent...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3744092/ https://ncbi.nlm.nih.gov/pubmed/23529697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1740774513480961 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|